Pernicious anemia. Early identification to prevent permanent sequelae

Area of Science:

• Hematology
• Neurology
• Gastroenterology

Background:

• Pernicious anemia is characterized by megaloblastic hematopoiesis, low serum cobalamin, and impaired vitamin B12 absorption.
• Recent findings indicate that neurologic complications of pernicious anemia may be less severe and more responsive to treatment than previously thought.
• These neurological issues can manifest without the typical anemia or macrocytosis.

Purpose of the Study:

• To summarize the diagnostic criteria for pernicious anemia.
• To discuss the evolving presentation of neurologic disorders associated with pernicious anemia.
• To emphasize the significance of identifying low cobalamin levels in patients with neurological symptoms, even without anemia.

Main Methods:

• Review of recent studies and clinical observations regarding pernicious anemia and its neurological manifestations.
• Analysis of diagnostic markers including hematopoiesis, serum cobalamin levels, and vitamin B12 absorption tests.
• Correlation of clinical presentation with laboratory findings.

Main Results:

• Pernicious anemia diagnosis is confirmed by megaloblastic hematopoiesis, low serum cobalamin, and vitamin B12 malabsorption correctable with intrinsic factor.
• Neurologic disorders in pernicious anemia patients are increasingly recognized as potentially less severe and highly treatable.
• Low serum cobalamin levels in patients with neurological deficits, irrespective of anemia status, warrant clinical attention.

Conclusions:

• Early diagnosis and treatment of pernicious anemia are crucial, especially when neurological symptoms are present.
• The absence of anemia or macrocytosis should not preclude the investigation of vitamin B12 deficiency.
• Monitoring serum cobalamin levels is essential for managing pernicious anemia and its neurological sequelae.